Cargando…
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
BACKGROUND: Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab. METHODS: This analysis was conducted on patients with pat...
Autores principales: | Palmerini, Emanuela, Seeger, Leanne L., Gambarotti, Marco, Righi, Alberto, Reichardt, Peter, Bukata, Susan, Blay, Jean-Yves, Dai, Tian, Jandial, Danielle, Picci, Piero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824947/ https://www.ncbi.nlm.nih.gov/pubmed/33482769 http://dx.doi.org/10.1186/s12885-020-07739-8 |
Ejemplares similares
-
Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum
por: Bukata, Susan V., et al.
Publicado: (2021) -
Malignancy in Giant Cell Tumor of Bone: A Review of the
Literature
por: Palmerini, Emanuela, et al.
Publicado: (2019) -
Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone
por: Rutkowski, Piotr, et al.
Publicado: (2015) -
High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?
por: Righi, Alberto, et al.
Publicado: (2015) -
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
por: Engellau, Jacob, et al.
Publicado: (2018)